ODT News and Press, Odonate Therapeutics Inc. From 04/07/21

Gainers: Odonate Therapeutics (ODT) +34%, Ocugen (OCGN) +24%, Titan Medical (TMDI) +15%, Frequency Therapeutics (FREQ) +14, 9 Meters Biopharma (NMTR) +10%%.Losers: FibroGen (FGEN) -39%, Homology Medicines (FIXX) -18%, Galectin Therap...

Gainers: [[AKBA]] +12.1%. [[SYBX]] +7.1%. [[ARDX]] +5.2%. [[ODT]] +4.9%. [[BYND]] +4.2%.Losers: [[FGEN]] -29.2%. [[FIXX]] -10.2%. [[MAXN]] -6.8%. [[IONS]] -5.8%. [[OM]] -5.4%. For further details see: AKBA, SYBX, FGEN and FIXX among after-hours movers

Top Penny Stocks For Your List Right Now Penny stocks are some of the highest risk investments you can make. But their innate ability to record explosive gains is undeniable. What are penny stocks ? All we’re talking about here are stocks under $5. According to the Securities...

Gainers: Dolphin Entertainment (DLPN) +163%.Benitec Biopharma (BNTC) +88%.Liquid Media (YVR) +51%.Takung Art (TKAT) +35%.Evolve Transition Infrastructure (SNMP) +27%.Genius Brands International (GNUS) +17%.The ONE Group Hospitality (STKS) +17%.Glory Star New Media (GSMG) +16%.Funko ...

Following this morning's announcement that it was abandoning tesetaxel for breast cancer following negative feedback from the FDA in a pre-NDA meeting, Jefferies analyst Michael Yee has cut shares of Odonate Therapeutics (ODT) from buy to hold.He is also lowering his price target to $4 f...

Gainers: Support.com (SPRT) +246%.Jiayin Group (JFIN) +40%.Summer Infant (SUMR) +36%.Hall of Fame Resort & Entertainment (HOFV) +32%.Recon Technology (RCON) +31%.Seneca Biopharma (SNCA) +24%.Dyadic International (DYAI) +22%.DarioHealth (DRIO) +20%.Marker Therapeutics (MRKR) ...

Shares of Odonate Therapeutics (NASDAQ: ODT) were crashing 78% as of 11:38 a.m. EDT on Monday. The huge drop came after Odonate announced that it's discontinuing the development of tesetaxel and will "wind down the operations of the Company." Today's news underscores the risks i...

Odonate Therapeutics (ODT) shares plummet more than 75% during premarket trading after the company announces discontinuation of development of its orally administered chemotherapy agent tesetaxel.The company's conclusion that the clinical data package for tesetaxel is...

Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the dev...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020. As ...